EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Global seroprevalence of anti-HEV antibodies in pregnant women: a systematic meta-analysis

Octavian SAJIN, Adela TURCANU, Veaceslav GUTU, Nina IZIUMOV, Valentina BLAJ

One Health & Risk Management · 31.03.2026 · 7 (2) · 18-33

DOI: 10.38045/ohrm.2026.2.02 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift One Health & Risk Management, online erschienen am 31.03.2026. Verfasst von Octavian SAJIN und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hepatitis E virus (HEV) represents a significant public health concern during pregnancy, being associated with severe maternal and fetal complications. This meta-analysis aimed to estimate the global seroprevalence of anti-HEV IgG and IgM antibodies among pregnant women. Materials and methods. A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. Observational studies were identified in PubMed, Scopus, and Web of Science. Pooled seroprevalence estimates were calculated using a random-effects model. Heterogeneity was assessed using Cochran’s Q and the I² statistic, while publication bias was evaluated by funnel plots and Egger’s regression test.

Results

Thirty studies from diverse geographic regions were included. The pooled global seroprevalence of anti-HEV IgG was 11.76% (95% CI: 9.45–14.54), indicating widespread prior exposure. Anti-HEV IgM seroprevalence, reflecting recent infection, was 1.07% (95% CI: 0.61–1.86). Substantial heterogeneity was observed for both markers (I² > 95%), reflecting marked regional variability. No statistically significant small-study effects were detected by Egger’s regression (p > 0.05).

Conclusions

HEV exposure among pregnant women is common globally, with pronounced regional differences, whereas recent infection appears relatively rare at the global level. These findings highlight the need for region-specific surveillance, improved diagnostic standardization, and targeted preventive strategies to reduce HEV-related risks during pregnancy.

Zitieren

APA

SAJIN, O., TURCANU, A., GUTU, V., IZIUMOV, N., & BLAJ, V. (2026). Global seroprevalence of anti-HEV antibodies in pregnant women: a systematic meta-analysis. One Health & Risk Management, 7(2), 18-33. https://doi.org/10.38045/ohrm.2026.2.02

Vancouver

SAJIN O, TURCANU A, GUTU V, IZIUMOV N, BLAJ V. Global seroprevalence of anti-HEV antibodies in pregnant women: a systematic meta-analysis. One Health & Risk Management. 2026;7(2):18-33. doi:10.38045/ohrm.2026.2.02

BibTeX
@article{SAJIN2026,
  author = {SAJIN, Octavian and TURCANU, Adela and GUTU, Veaceslav and IZIUMOV, Nina and BLAJ, Valentina},
  title = {Global seroprevalence of anti-HEV antibodies in pregnant women: a systematic meta-analysis},
  journal = {One Health & Risk Management},
  year = {2026},
  volume = {7},
  number = {2},
  pages = {18--33},
  doi = {10.38045/ohrm.2026.2.02}
}
Kostenlos starten →